MedTrace Logo

Systematic Evaluation of Antiviral Medication in Schizophrenia

NCT00514449 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2018-06-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine whether antiviral medication will help improve psychotic symptoms and cognition in individuals early in the course of schizophrenia or schizoaffective disorder who are exposed to herpes simplex virus, type 1 (HSV 1), a virus that causes commonly occurring and recurrent cold sores.

Conditions

Interventions

DRUG

Valacyclovir

1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic

DRUG

Placebo

2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Wayne State University

    collaborator OTHER

  • Konasale Prasad

    lead OTHER

Principal Investigators

  • Konasale Prasad, MD · Western Psychiatric Institute and Clinic

  • Vishwajit Nimgaonkar, MD, PhD · Western Psychiatric Institute and Clinic

  • Matcheri Keshavan, MD · Wayne State University

  • Rajaprabhakaran Rajarethinam, MD · Wayne State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514449 on ClinicalTrials.gov